Daxor Corporation (NYSE: DXR) is an innovative medical instrumentation and biotechnology company focused on blood volume measurement. We developed and market the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Since its introduction, the BVA-100 Blood Volume Analyzer has been used in over 40,000 clinical cases and numerous research studies highlighting its potential to transform therapy. The BVA technology has the potential to improve hospital performance metrics in a broad range of surgical and medical conditions including heart failure and critical care by better informing treatment strategies, resulting in significantly better patient outcomes. Our mission is to partner with clinicians to incorporate BVA technology into standard clinical practice and improve the quality of life for patients.

Company Profile

350 Fifth Ave., Suite 4740
New York, NY 10118




Intraday stock chart for DXR


Michael Feldschuh

CEO and President

Robert Michel

Chief Financial Officer

Jonathan Feldschuh

Chief Scientific Officer

Soren Thompson

VP Business Development

Kathryn A. Kornafel

Vice President Marketing & Commercial Development

View Management Team

Past Six Months

6 month stock chart for DXR

Investor Relations

Bret Shapiro
377 Oak Street
Garden City, NY 11530
Phone: 516-222-2560
E-mail: brets@coreir.com

Transfer Agent

Continental Stock Transfer
1 State Street, 30th Floor
New York, NY 10004
Phone: 212-509-4000
E-mail: cstmail@continentalstock.com


Withum Smith & Brown
1411 Broadway, 9th Floor
New York, NY 10018
Phone: 212-751-9100
Fax: 212-750-3262
E-mail: mstallone@withum.com

Corporate Counsel

Peter Fetzer
Foley & Lardner LLP
777 East Wisconsin Avenue
Milwaukee, Wisconsin 53202
Phone: 414-271-2400
Fax: 414-297-4900

Subscribe to IR news and filing alerts

You can opt out at any time. We do not share or sell your info.